ALKERMES PLC (ALKS)

NASDAQ:ALKS, an undervalued stock with good fundamentals.

ALKERMES PLC (NASDAQ:ALKS): good value for what you're paying.

Alkermes to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI...

Alkermes to Participate in Two Upcoming Investor Conferences

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference...

Bullish Two Hundred Day Moving Average Cross - ALKS

Alkermes plc Reports Third Quarter 2024 Financial Results

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong...

Alkermes to Report Third Quarter Financial Results on October 24, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to...

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Alkermes (ALKS) Shares Cross Below 200 DMA

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on...

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy...

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel...

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program...

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22nd Annual...

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of...

ALKS Stock Earnings: Alkermes Beats EPS, Beats Revenue for Q2 2024

ALKS stock results show that Alkermes beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

ALKS Stock Earnings: Alkermes Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alkermes (NASDAQ:ALKS) just reported results for the second quarter of 2024.Alk...

ALKS Crosses Above Key Moving Average Level

Alkermes plc Reports Second Quarter 2024 Financial Results

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2024. "Our second quarter results reflect solid...

Alkermes to Report Second Quarter Financial Results on July 24, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to...

"Rule Breaker Investing" Stock Pick Review: The Big One

Looking back at 30 five-stock samplers picked from 2015 to 2021.

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study...

Alkermes to Participate in Two Upcoming Investor Conferences

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor...